Conference Track

Advances in HCV Management Strategies With Approved Agents

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Prolonged Low-Dose Peginterferon alfa Maintenance Therapy for Previous Nonresponders to Peginterferon/Ribavirin Does Not Reduce Liver Disease Progression Rate
Patient Education Significantly Improves Adherence to Peginterferon alfa-2b/Ribavirin Therapy Among Patients Infected With HCV Genotype 2/3
Only Baseline Histologic Severity Predicts SVR to Peginterferon/Ribavirin in a Cohort of Individuals With Same Strain of HCV Genotype 1b
Patient Weight Not a Factor in SVR Rates Among Hepatitis C Patients Treated With Weight-Based Peginterferon alfa-2b
Discontinuation of Ribavirin at Week 6 in Patients With Rapid Response to Peginterferon alfa-2a and Ribavirin Results in Comparable SVR Rate in HCV Genotype 2/3 Patients With RNA ≤ 700,000 IU/mL
Longer Treatment With Peginterferon and Weight-Based Ribavirin Beneficial for Slow Responders to HCV Therapy
RVR Strong Predictor of SVR to Peginterferon alfa-2b Plus Ribavirin in Chronic Hepatitis C
CIFN-Based Therapy Leads to Posttreatment Virologic Response in Select Group of Treatment-Experienced Patients but Associated With Early Treatment Discontinuation
High-Dose Peginterferon alfa-2a Associated With Superior Early Virologic Suppression vs Standard Peginterferon alfa-2a in Treatment-Naive HCV Genotype 1 Patients
ACCELERATE Study: HCV Genotype 2/3 Patients Without Rapid Virologic Response Have Low Rate of SVR With 16 or 24 Weeks of Therapy
Daily Consensus Interferon Plus Ribavirin Achieves Higher SVR Rates in Noncirrhotic Previous Peginterferon alfa/Ribavirin Nonresponders
REPEAT Study Shows Extension of Peginterferon alfa-2a/Ribavirin Treatment Duration Improves SVR Rates Among HCV-Infected Peginterferon alfa-2b/Ribavirin Nonresponders
Higher SVR Rates Not Observed When More Sensitive PCR Assay (< 15 vs 50 IU/mL) Used to Detect RVR for Response-Guided Therapy in HCV-Infected Patients
Multivariate Regressional Analyses of Pooled HCV Genotype 1 Patient Data Find HCV RNA and Ribavirin Dose Predictive of RVR
HCV FibroSURE and FIBROSpect II Comparable for Fibrosis Staging in Chronic Hepatitis C Patients

Expert Analysis

Advances in HCV Management Strategies With Approved Agents

Faculty:

Raymond T. Chung, MD
Mitchell L. Shiffman, MD
Mark S. Sulkowski, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data on the use of agents approved by the US Food and Drug Administration for the treatment of patients with chronic hepatitis C and strategies for managing their adverse effects
Summarize new insights into factors associated with response and nonresponse to treatment for chronic hepatitis C
Describe the latest findings on retreatment strategies for patients with hepatitis C virus with previous nonresponse to interferon and ribavirin-based regimens

CME CREDIT INFORMATION

Release Date: 12/20/07

Expiration Date: 12/19/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.